186 related articles for article (PubMed ID: 17970893)
1. Off-label uses of rituximab in dermatology.
Carr DR; Heffernan MP
Dermatol Ther; 2007; 20(4):277-87. PubMed ID: 17970893
[TBL] [Abstract][Full Text] [Related]
2. Innovative uses of rituximab in dermatology.
Carr DR; Heffernan MP
Dermatol Clin; 2010 Jul; 28(3):547-57. PubMed ID: 20510764
[TBL] [Abstract][Full Text] [Related]
3. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus.
Schadlow MB; Anhalt GJ; Sinha AA
J Drugs Dermatol; 2003 Oct; 2(5):564-7. PubMed ID: 14558407
[TBL] [Abstract][Full Text] [Related]
4. Rituximab: a B-cell depletion therapy for dermatologic disease.
Prajapati V; Mydlarski PR
Skin Therapy Lett; 2007; 12(6):6-9. PubMed ID: 17762903
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in non-haematological disorders of adults and its mode of action.
McDonald V; Leandro M
Br J Haematol; 2009 Aug; 146(3):233-46. PubMed ID: 19466979
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.
Allen KJ; Wolverton SE
J Drugs Dermatol; 2007 Sep; 6(9):883-9. PubMed ID: 17941359
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: applications in dermatology.
Fatourechi MM; el-Azhary RA; Gibson LE
Int J Dermatol; 2006 Oct; 45(10):1143-55; quiz 1155. PubMed ID: 17040427
[TBL] [Abstract][Full Text] [Related]
8. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
9. Rituximab: Uses in Dermatology.
Gleghorn K; Wilson J; Wilkerson M
Skin Therapy Lett; 2016 Sep; 21(5):5-7. PubMed ID: 27603326
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in severe pemphigus.
Schmidt E; Goebeler M; Zillikens D
Ann N Y Acad Sci; 2009 Sep; 1173():683-91. PubMed ID: 19758216
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic potential of anti-CD20 "what do B-cells do?".
Eisenberg R; Looney RJ
Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
[No Abstract] [Full Text] [Related]
14. A review of rituximab in cutaneous medicine.
Scheinfeld N
Dermatol Online J; 2006 Jan; 12(1):3. PubMed ID: 16638371
[TBL] [Abstract][Full Text] [Related]
15. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature.
Barnadas M; Roe E; Brunet S; Garcia P; Bergua P; Pimentel L; Puig L; Francia A; García R; Gelpí C; Sierra J; Coll P; Alomar A
J Eur Acad Dermatol Venereol; 2006 Jan; 20(1):69-74. PubMed ID: 16405612
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.
Heizmann M; Itin P; Wernli M; Borradori L; Bargetzi MJ
Am J Hematol; 2001 Feb; 66(2):142-4. PubMed ID: 11421295
[TBL] [Abstract][Full Text] [Related]
17. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab).
Morrison LH
J Am Acad Dermatol; 2004 Nov; 51(5):817-9. PubMed ID: 15523367
[TBL] [Abstract][Full Text] [Related]
18. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
Zhou X; Hu W; Qin X
Oncologist; 2008 Sep; 13(9):954-66. PubMed ID: 18779537
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
Roll P; Dörner T; Tony HP
Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
[TBL] [Abstract][Full Text] [Related]
20. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
